Top

BY Ron Gilmore

A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of Texas MD Anderson Cancer Center demonstrated significantly increased progression-free survival in multiple myeloma patients.

The study, which followed 202 patients, compared busulfan with melphalan versus melphalan alone. Progression-free survival was 65 months for patients receiving combination...

Busulfan and melphalan chemotherapy combination

BY Ron Gilmore

Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes...

BY Scott Merville

Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge...

BY Scott Merville

Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping cancer.

After years of diligent, groundbreaking research, MD Anderson physician-scientists are putting natural killer cells – NK cells for short – to work in a series of clinical trials for a variety of cancers through the cancer center’s Moon Shots Program™.

“These white...

Natural killer cells derived from cord blood used to kill blood cancers

BY Ron Gilmore

The biopharmaceutical drug blinatumomab is more effective for the treatment of relapsed or treatment-resistant acute lymphoblastic leukemia...

BY MD Anderson staff

In the modern world of biomedical research, collaborations between academic institutions and pharmaceutical and biotech companies have become...

BY Ronda Wendler

Chemistry professor Bindu Chakravarty rarely missed a day teaching at Houston Community College. So when she called in sick one morning, it...

BY Bryan Tutt

Patients diagnosed with blood-related cancers such as leukemia, lymphoma and multiple myeloma often undergo what is called a hematopoietic...